Oncology Pharma Inc (ONPH) Fair Value & Analysis
Financial Services · US · Market cap $2.6M
Oncology Pharma Inc
ONPH · US
Strengths
Risks
Fair value as of: Aug 21, 2026
From 5 valuation models · updated today
Share price −25.3% over the past month.
Below-average quality, currently priced close to our fair value.
What matters now
- The price is below even our cautious bear case ($0.0563). The market is more pessimistic than our downside scenario.
- The price sits close to our fair value, market and models broadly agree here, little valuation tension.
- Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
- For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 21, 2026.
How to read this chart
60‑month range $0.0001 – $36.40 · the $0.0523 price screens below the $0.0563 fair value. Dashed = 300-day average. As of Aug 21, 2026.
Analysis
Oncology Pharma Inc (ONPH) currently trades at $0.0523, while our model-based Fair Value estimate is $0.0563, implying the stock looks roughly 7.7% fairly valued today. The Quality Score stands at 40/100 (below-average quality), in the Financial Services sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at $10.2K. Fundamentals as of Aug 21, 2026
The share trades about 74% below its 52-week high, currently above its 200-day average. For context, the median of 10 Financial Services peers we cover trades at -61% fair-value upside, at 8%, ONPH screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 5 models by family
Widest divergence: Growth DCF ($0.0900) versus Asset-Based ($0.0200). Highest evidence: Growth DCF (72).
Notify me when ONPH reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
Figures from reported company fundamentals · as of Aug 21, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 45 · Market factors (momentum, volatility) 62
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019.
Full company description
Oncology Pharma Inc., an oncology company, develops, manufactures, and commercializes therapeutics. The company has a collaboration and licensing agreement with Kalos Therapeutics Inc. for exploring treatment opportunities of the COVID-19 virus. The company was formerly known as SourcingLink.net Inc. and changed its name to Oncology Pharma Inc. in June 2019. Oncology Pharma Inc. was incorporated in 1993 and is based in San Francisco, California.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2002 – FY2026 · reported fiscal years
Oncology Pharma Inc reported revenue of $10.2K in FY2013 versus $3.7M in FY2002, a compound −41.4%/yr. Reported net income was −$5.8K in FY2026.
Watch ONPH: get an alert when its fair value changes →
Peer Group
Shell Companies · 95 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Shell Companies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Shell Companies stocks, each showing price versus our Fair Value estimate (as of Aug 21, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| The Coca-Cola Company COLA | C$30.34 | C$10.62 | -65% |
| Lionheart III Corp LION | $11.73 | $18.15 | +55% |
| Agriculture & Natural Solutions Acquisition Corporation ANSC | $11.46 | $4.13 | -64% |
| AA Mission Acquisition Corp AAM | $0.0390 | $0.0394 | +1% |
| GP-Act III Acquisition Corp GPAT | $11.16 | $4.30 | -61% |
| Metals Acquisition Corp MTAL | $10.24 | $20.48 | +100% |
| Berto Acquisition Corp TACO | $10.45 | $2.73 | -74% |
| Axiom Intelligence Acquisition Corp AXIN | $10.29 | $1.46 | -86% |
| Bold Eagle Acquisition Corp BEAG | $10.75 | $4.00 | -63% |
| Lionheart Holdings CUB | $10.88 | $5.06 | -53% |
Compare Oncology Pharma Inc with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Financial Services stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Oncology Pharma Inc (ONPH) overvalued or undervalued?
What is the fair value of ONPH?
What is the quality score of ONPH?
What is the revenue of Oncology Pharma Inc (ONPH)?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Oncology Pharma Inc and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.